Skip to content

Dysphagia, QoL and Attitudes Towards PEG in ALS Patients

Dysphagia, Quality of Life and Attitudes Towards Percutaneous Endoscopic Gastrostomy in Patients With Amyotrophic Lateral Sclerosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05336760
Acronym
ALSDPEG
Enrollment
60
Registered
2022-04-20
Start date
2023-01-01
Completion date
2026-03-31
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Brief summary

In Amyotrophic Lateral Sclerosis, dysphagia has a high incidence. With deterioration of swallowing function, percutaneous endoscopic gastrostomy (PEG) tube is recommended to ensure sufficient and safe oral intake. Dysphagia and PEG placement alter quality of life (QoL). However, QoL and attitudes toward PEG remain largely unexplored. The purpose of this study is to monitor the swallowing function in relationship to QoL and attitudes toward PEG tube insertion and feeding.

Detailed description

The purpose of this study is to monitor the deterioration of swallowing function in ALS patient population, and to explore its impact on QoL and attitudes toward PEG tube insertion and feeding in the course of the disease. It will take maximum of 60 minutes to fully evaluate the swallowing function and complete the questionnaires. The evaluation procedure will be repeated every 3 months until PEG tube insertion, which will allow us to closely monitor the swallowing function in a relation to attitudes toward PEG and QoL. The data obtained from this study should contribute significantly to the knowledge of QoL in ALS patients with dysphagia, and it will allow for a comparison of QoL in ALS patients with and without PEG tube. This study will also expand the understanding of attitudes in ALS patients and their relatives toward PEG, and the impact of those attitudes on the decision-making process.

Interventions

IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.

DIAGNOSTIC_TESTMann Assessment of Swallowing Ability (MASA)

MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.

The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).

Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.

Sponsors

University Medical Centre Ljubljana
CollaboratorOTHER
University Rehabilitation Institute, Republic of Slovenia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for patients: * 18 years of age or older * diagnosis of ALS * follow-up at University Medical Centre Ljubljana, Division of Neurophysiology, every 3 months * be able to visit the study site for in-person procedures every 3 months Inclusion Criteria for relatives: * at least 18 years of age

Exclusion criteria

for patients: * co-existing illness or disorder that could influence the swallowing function independently of the ALS diagnosis * clinically significant cognitive deterioration or dementia at enrollment, as determined by the ALS study neurologist

Design outcomes

Primary

MeasureTime frameDescription
Penetration-Aspiration Scale (PAS) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)PAS is an 8-point scale used to determine swallowing safety. Levels 1 and 2 are considered safe, levels \>3 indicate penetration or aspiration and are considered unsafe.
Yale Residue Severity Rating Scale (YRSRS) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)YRSRS is a validated measure of swallowing efficiency using an image-based assessment to determine post-swallow pharyngeal residue: location and severity. It is assessed using a 5-point ordinal scale (from 1=0 % residue to 5=50 % residue).
Iowa Oral Performance Instrument (IOPI) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)IOPI is a device which measures tongue strength (in kilopascals; kPa) and endurance (in seconds) while the participant presses the bulb with the front or the base of their tongue to the hard palate.
Mann Assessment of Swallowing Ability (MASA) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)MASA is a standard clinical swallowing assessment protocol administered by the speech-language therapist. Total score ranges from 38-200. Lower score indicates higher impairment.
Eating Assessment Tool 10 (EAT-10) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)EAT-10 is a validated self-administered dysphagia severity symptom survey including 10 items and a five-point scale (0=no problem to 4=sever problem). Higher total score indicates higher impairment.
Swallowing Quality of Life Questionnaire (SWAL-QoL) changeAt baseline and every 3 months until PEG insertion, 3 and 6 months after PEG insertionSWAL-QoL is a 44-item standardised psychometric scale that measures swallowing-related QoL across 10 domains. Scores for each individual domain and a total SWAL-QoL score are calculated. Total score ranges from 0-100 (100 indicating the most favourable state).
Questionnaire on Attitudes Toward PEG Tube Feeding and Insertion Procedure changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)The questionnaire comprises 10 questions. The participants specify their level of agreement on a five-point Likert-type scale (1=strongly disagree, 5= strongly agree).

Secondary

MeasureTime frameDescription
ALS Functional Rating Scale-Revised (ALSFRS-R) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)ALSFRS-R is a 12-tem ALS-specific assessment of global functioning using a five-point scale (0=not able, 4= normal ability), with 48 points representing normal function.
Maximal Expiratory Pressure (MEP) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)Standard clinical respiratory assessment of MEP (in cmH2)
Functional Oral Intake Scale (FOIS) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)FOIS is a validated 7-point scale demonstrating an individual's ability of daily oral food intake (1=no oral intake, 7=total oral intake with no restrictions).
Dysphagia Outcome and Severity Scale (DOSS) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)DOSS is a 7-point scale that rates the functional severity of dysphagia based on objective assessment and provides information on diet recommendations, independence level and type of nutrition necessary (level 7=normal swallowing function, level 1=severe dysphagia).
BMI changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)Body mass index (in kg/m\^2)
Forced Vital Capacity (FVC) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)Standard clinical respiratory assessment of FVC (in %)
Peak Cough Flow (PCF) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)Standard clinical respiratory assessment of PCF (in L/min)
Maximal Inspiratory Pressure (MIP) changeDifference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)Standard clinical respiratory assessment of MIP (in cmH2)

Countries

Slovenia

Contacts

Primary ContactMetka Moharić, MD, PhD
metka.moharic@ir-rs.si+386 1 4758441

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026